Skip to main content

Seaport Therapeutics, Inc.

corporate_fare Company Profile

Seaport Therapeutics, Inc.

SPTX·NASDAQ·Life Sciences·CIK 0002042347

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing new neuropsychiatric medicines. The company creates therapeutic candidates for conditions like depression and anxiety disorders. Its proprietary Glyph technology platform is central to its development efforts. This platform is designed to improve oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations, hepatotoxicity, and other side effects. All therapeutic candidates currently in development utilize this Glyph platform, with research and development activities specifically targeting neuropsychiatric medicines. Seaport Therapeutics, Inc. serves clinicians and key opinion leaders within the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is headquartered in Boston, Massachusetts.

Seaport Therapeutics, Inc. (NASDAQ:SPTX) is a publicly traded company in the Life Sciences sector. Wiseek monitors SPTX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Seaport Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances
  • Seaport Therapeutics Q2 2026: $427M Cash, Pipeline Progress, and $260M Upsized IPO
  • Seaport Therapeutics Q2 Cash Surges to $427M, Pipeline Advances with Multiple Data Readouts Ahead
  • Seaport Therapeutics Reports Q1 Results, Confirms IPO Proceeds Extend Cash Runway into 2029
  • Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, and Appoints Biotech Veteran to Board

Dilution Risk

Low risk

Filing-implied dilution signals for SPTX, detected from its recent SEC filings · based on capital-structure filings through 2026-05-01.

1 recent capital raise

Initial Public Offering Priced · Significant Capital Raised

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$23.62
52-week range · as of 2026-08-03 $14.85 – $23.62
Market cap
$1.26B
Volume
112.4K (0.8× avg)
3-mo avg 132.8K
Live data · 2026-08-08 04:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SPTX - Latest Insights

SPTX
Aug 03, 2026, 7:11 AM EDT
Filing Type: 10-Q
Importance Score:
8
Seaport Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances
Price at Filing: $20.46
Real-time Price: $23.62 info
Change: +$3.16 (+15%) info
Market Cap: $1.264B info
Sentiment: Neutral
View Wiseek Article
SPTX
Aug 03, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Seaport Therapeutics Q2 2026: $427M Cash, Pipeline Progress, and $260M Upsized IPO
Price at Filing: $20.46
Real-time Price: $23.62 info
Change: +$3.16 (+15%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
Aug 03, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Seaport Therapeutics Q2 Cash Surges to $427M, Pipeline Advances with Multiple Data Readouts Ahead
Price at Filing: $20.46
Real-time Price: $23.62 info
Change: +$3.16 (+15%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
Jun 08, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
9
Seaport Therapeutics Reports Q1 Results, Confirms IPO Proceeds Extend Cash Runway into 2029
Price at Filing: $16.44
Real-time Price: $23.62 info
Change: +$7.18 (+44%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
Jun 08, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
9
Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, and Appoints Biotech Veteran to Board
Price at Filing: $16.44
Real-time Price: $23.62 info
Change: +$7.18 (+44%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
Jun 08, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, Advances Clinical Pipeline
Price at Filing: $16.44
Real-time Price: $23.62 info
Change: +$7.18 (+44%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
May 11, 2026, 7:54 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
General Atlantic Discloses 11.5% Stake in Seaport Therapeutics Following IPO Participation
Price at Filing: $15.25
Real-time Price: $23.62 info
Change: +$8.37 (+55%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
May 06, 2026, 4:26 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
ARCH Venture Partners Discloses 11.9% Stake in Seaport Therapeutics Post-IPO, Including $19.8M IPO Purchase
Price at Filing: $16.00
Real-time Price: $23.62 info
Change: +$7.62 (+48%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
May 04, 2026, 6:02 PM EDT
Filing Type: 4
Importance Score:
9
ARCH Venture Partners Makes $19.8M Open Market Purchase in Seaport Therapeutics Post-IPO, Signaling Strong Confidence
Price at Filing: $16.70
Real-time Price: $23.62 info
Change: +$6.92 (+41%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
May 01, 2026, 5:31 PM EDT
Filing Type: 424B4
Importance Score:
9
Seaport Therapeutics Prices Initial Public Offering at $18.00 Per Share, Raising $254.88 Million for Clinical Development
Price at Filing: $19.78
Real-time Price: $23.62 info
Change: +$3.84 (+19%) info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article
SPTX
Apr 30, 2026, 9:58 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Seaport Therapeutics Prices Upsized IPO, Signaling Strong Market Demand
Price at Filing: N/A
Real-time Price: $23.62 info
Change: N/A info
Market Cap: $1.264B info
Sentiment: Positive
View Wiseek Article